Quarterly Report Card: Special Research on AxoGen, BioLife, Perseon, CONMED, and Cutera
NEW YORK, February 27, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including AxoGen (NASDAQ: AXGN), BioLife (NASDAQ: BLFS), Perseon (NASDAQ: BSDM), CONMED (NASDAQ: CNMD), and Cutera (NASDAQ: CUTR). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
AXGN Research Report: ( http://get.analystsreview.com/pdf/?c=AxoGen&d=27-Feb-2015&s=AXGN ),
BLFS Research Report: ( http://get.analystsreview.com/pdf/?c=BioLife&d=27-Feb-2015&s=BLFS ),
BSDM Research Report: ( http://get.analystsreview.com/pdf/?c=Perseon&d=27-Feb-2015&s=BSDM ),
CNMD Research Report: ( http://get.analystsreview.com/pdf/?c=CONMED&d=27-Feb-2015&s=CNMD ),
CUTR Research Report: ( http://get.analystsreview.com/pdf/?c=Cutera&d=27-Feb-2015&s=CUTR ).
============
--
Analyst Update: Quarterly Results, Upcoming Earnings, Appointments, and Launches
Reviewed by: Rohit Tuli, CFA®
Global equities dipped on Thursday as investor enthusiasm was dampened by a pullback in oil prices related to rising inventories, while the dollar rose as economic data drove expectations that the Federal Reserve will raise interest rates. In the U.S., consumer prices fell in the 12 months through January, the first such decline since 2009 as gasoline prices continued to tumble. The S&P 500 ended down 0.15% to 2110.74, Dow was down 0.06% to 18214.42, while Nasdaq was a bright spot in U.S. equities, rising 0.42% to 4987.89 on news of a technology deal. The pan-European Euro Stoxx 600 Index closed up 0.9% higher as investors reacted to a raft of corporate earnings and fresh economic data. The latest GDP data from Spain and UK confirmed a year on year growth of 2% and 2.7%, respectively in the last quarter. The German unemployment rate also stayed at a record low in February. In Asia, Japanese shares outperformed the region by reaching a new multiyear high, but the rest of Asia traded mixed on Thursday.
AxoGen, Inc. (AxoGen), a leading medical technology company, expects to report a 61% YoY growth in its Q4 2014 revenue at $4.79 million. For full year 2014, revenue is expected to be at $16.8 million, representing a 54% YoY increase. The Company intends to report the complete financial results in early March 2015.
BioLife Solutions, Inc. (BioLife) announced that it has started Good manufacturing Practice (GMP) manufacturing of low molecular weight (LMD) Dextran solutions for use in thawing human cells after cryopreservation. The Company launched these new products in response to an extended worldwide shortage of dextran solutions that are used off-label to transition frozen cells to room temperature.
Perseon Corp (Perseon), formerly known as BSD Medical Corporation, has appointed Ben Beckham as Vice President of North American Sales, effective February 16, 2015. Mr. Beckham is an accomplished and performance-driven life sciences executive with over 20 years of experience in medical sales management and marketing, said the Company.
CONMED Corporation (CONMED) announced its Q4 and full-year 2014 financial results. For the quarter, diluted EPS increased to $0.41 from $0.36 in Q4 2013; while sales witnessed a year on year drop of 4.0% to $195.0 million.
Cutera, Inc. (Cutera) reported its Q4 2014 financial results. Revenue increased 15% YoY to $25.5 million, driven by a 33% YoY growth in the U.S. resulting from its recently launched new products - enlighten and excel HR. Net loss however widened to $1.6 million, or $0.11 per diluted share, from $0.3 million net loss or $0.02 per loss diluted share in Q4 2013.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article